Literature DB >> 21474683

Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.

Takaaki Nozawa1, Teruko Imai.   

Abstract

Intestinal absorption of temocapril, a prodrug of temocaprilat, was evaluated in an in situ rat jejunal perfusion model under various conditions of luminal pH and in the presence and absence of carboxylesterase-mediated hydrolysis. Temocapril was more easily taken up by mucosal cells at a luminal pH of 5.4 than at pH 6.4 or 7.4 and was extensively hydrolyzed to temocaprilat in mucosal cells. The hydrolysis was limited by the intrinsic clearance and the influx rate at luminal perfusate pHs of 5.4 and 7.4, respectively. Temocaprilat, derived from temocapril, was transported into both mesenteric vein and jejunal lumen according to pH partition theory. The net absorption of both temocapril and temocaprilat was highest at a luminal perfusate pH of 5.4. When both the luminal and venous fluid were at pH 7.4, temocaprilat was transported approximately 3-fold faster into the lumen than into the vein, due presumably to the greater surface area of the brush border membrane because of the presence of microvilli. Under carboxylesterase-inhibited conditions, the hydrolysis of temocapril was inhibited by only 50%. It is postulated that serine esterases located on the membranes of the epithelial cells were responsible for the residual hydrolysis. We have confirmed that temocapril is most easily absorbed in the proximal intestine after meals, due to prolongation of the gastric emptying time, the lower intraluminal pH caused by secretion of bile acid, and the interaction between serine esterases and the digesta.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474683     DOI: 10.1124/dmd.110.037937

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats.

Authors:  Yoshiki Matsuda; Yoshihiro Konno; Takashi Hashimoto; Mika Nagai; Takayuki Taguchi; Masahiro Satsukawa; Shinji Yamashita
Journal:  Pharm Res       Date:  2014-08-28       Impact factor: 4.200

2.  Nanoemulsions as novel oral carriers of stiripentol: insights into the protective effect and absorption enhancement.

Authors:  Rong Lu; Shan Liu; Qilin Wang; Xia Li
Journal:  Int J Nanomedicine       Date:  2015-07-31

3.  Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: enhanced bioavailability and in vitro anti-inflammatory activity.

Authors:  Frederick Yk Siu; Shaotang Ye; Hui Lin; Shoujun Li
Journal:  Int J Nanomedicine       Date:  2018-07-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.